Clinical Considerations for Immunoparesis in Multiple Myeloma
Open Access
Abstract
Multiple myeloma is a relatively common clonal plasma cell disorder, comprising 17% of hematologic malignancies. One of the hallmark features of this disease is immunoparesis, which is characterized by the suppression of immunoglobulin polyclonality. Though not entirely elucidated, the mechanism behind this process can be attributed to the changes in the tumor microenvironment. All treating clinicians must consider potential complications related to immunoparesis in the management of multiple myeloma. Though not explicitly described in large data series, the increased risk of infection in multiple myeloma is likely, at least in part, due to immunoglobulin suppression. Additionally, the presence of immunoparesis serves as a prognostic factor, conveying poorer survival and a higher risk of relapse. Even in the era of novel agents, these findings are preserved, and immunoglobulin recovery also serves as a sign of improved outcome following autologous HSCT. Though not within the diagnostic criteria for multiple myeloma, the presence and degree of immunoparesis should be at diagnosis for prognostication, and immunoglobulin recovery should be tracked following myeloablative therapy and autologous HSCT.Keywords
This publication has 46 references indexed in Scilit:
- Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balanceBlood Cancer Journal, 2013
- Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced ageAmerican Journal of Hematology, 2012
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementLeukemia, 2010
- Multiple Myeloma and Polyclonal HypogammaglobulinaemiaActa Medica Scandinavica, 2009
- Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapyCancer, 2008
- Immunoglobulin gene rearrangements and the pathogenesis of multiple myelomaBlood, 2007
- Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathyJournal of Experimental Medicine, 2007
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myelomaAmerican Journal of Hematology, 1989
- Suppression of polyclonal immunoglobulins in multiple myeloma: Relationship to the staging and other manifestations at diagnosisClinical Immunology and Immunopathology, 1980